$1.110
-0.039 (-3.48%)Zum Schluss
PLRX-News
PLRX-Events
Pliant Appoints New Board Members to Strengthen Oncology Drug Development
"In the second quarter, we continued to execute across the portfolio, led by strong enrollment in FORTIFY," said Bernard Coulie, President and Chief Executive Officer of Pliant. "With the appointments of Flavia and Robert to the board, Pliant now has deep global oncology drug development and commercialization expertise at this important time for our oncology program. We continue to make progress on our proprietary integrin-targeted drug-delivery platform and look forward to sharing more information on the platform soon."
Pliant CEO Announces Early Start of PLN-101095 Clinical Trial
"In the first quarter, our team showcased its clinical development capabilities, initiating FORTIFY, the Phase 1b trial of PLN-101095, ahead of schedule and dosing the first patient in April," said Bernard Coulie, President and Chief Executive Officer of Pliant. "We were excited to highlight encouraging recent data from the Phase 1a trial of PLN-101095 at AACR showing deepening responses and increasing time on treatment. The team continues to make progress on pipeline programs emerging from Pliant's proprietary integrin platform while evaluating opportunities to expand our clinical-stage pipeline."
Pliant Therapeutics Initiates FORTIFY Clinical Trial
Pliant Therapeutics announced the dosing of the first participant in the FORTIFY Phase 1b open-label indication expansion clinical trial of PLN-101095 in combination with pembrolizumab, in patients with immune checkpoint inhibitor -refractory advanced or metastatic solid tumors. PLN-101095 is an oral, small molecule, dual selective inhibitor of the integrins alphavbeta8 and alphavbeta1.
Pliant Therapeutics Updates PLN-101095 Clinical Data
Pliant Therapeutics announced the presentation of updated data from its Phase 1 trial of PLN-101095, in combination with pembrolizumab, in patients with immune checkpoint inhibitor-refractory advanced or metastatic solid tumors. The oral presentation was made at the Clinical Trials Mini Symposium of the American Association for Cancer Research (AACR) 2026 Annual Meeting. All responding patients showed large increases in plasma interferon gamma after a 14-day run-in period of monotherapy with PLN-101095. At Week 10, all responders maintained more than a 2-fold increase in IFN-gamma. No non-responders showed meaningful increases in IFN- gamma. In addition to IFN- gamma increases, all responding patients showed elevated plasma PD-L1 levels, known to be induced by increased IFN-gamma and a predictor of an improved ICI response. As increases in IFN-gamma have the potential to serve as a biomarker of TGF-beta inhibition and an early indicator of PLN-101095 anti-tumor activity. Pliant anticipates further study of this biomarker as part of the expansion cohorts in the Phase 1b trial. PLN-101095 was generally well tolerated across all doses evaluated with few discontinuations due to adverse events. Rash was the most common treatment-related adverse event, all Grade 1 or 2, and the majority of events occurred within the first 2 days of the initial pembrolizumab dose. One Grade 3 TRAE was observed.
Pliant Therapeutics Files $300M Mixed Securities Shelf
Pliant Therapeutics files $300M mixed securities shelf
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.